Our Team And The Power of imagination

Mehmood Khan, MD

Chief Executive Officer

Mehmood Khan, MD, is Chief Executive Officer and Board Member of Life Biosciences Inc. In his role as CEO, Dr. Khan provides strategic direction and operational oversight across the organization. His vision of a more efficient and effective drug development pathway will drive innovation in the science and technology that Life Biosciences advances. Dr. Khan previously served as Global Vice Chairman and Chief Scientific Officer of PepsiCo. He played a pivotal role in the company’s global R&D efforts to create breakthrough innovations in food, beverages, and nutrition, including the incorporation of healthier and more nutritious offerings across its portfolio. Dr. Khan also oversaw their global sustainability initiatives. Prior to joining PepsiCo, Dr. Khan served as President of Global R&D at Takeda Pharmaceuticals, leading the global efforts of one of the largest pharmaceutical companies in the world by revenue. Before moving into industry, Dr. Khan had a distinguished medical career as a practicing faculty member in endocrinology at the Mayo Clinic and Mayo Medical School where he served as Director of the Diabetes, Endocrine and Nutritional Trials Unit. Dr. Khan is a member of the Board of Directors of Reckitt Benckiser and Indigo Ag. He is also a member of the Visiting Committee on Advanced Technologies at the National Institute of Standards and Technology (NIST) and Chair of the U.S. Council on Competitiveness in Washington, DC. Dr. Khan earned his medical degree from the University of Liverpool Medical School, England and completed a fellowship in clinical endocrinology and nutrition in the Department of Medicine and Food Science and Nutrition at the University of Minnesota, Minneapolis. He is a Fellow of the Royal College of Physicians, London, a Fellow of the American College of Endocrinology, and holds two ad honorem PhDs in humanities and international law. He has been exclusively featured in numerous publications including Fast Company's 100 Most Creative People in Business.

John Amatruda, MD

President, R&D Operations

Throughout his 26-year career in drug research and development, Dr. John Amatruda has produced drugs that treat diabetes, obesity, cardiovascular disease and more. In addition to tenures as a professor at Yale University School of Medicine and The University of Rochester School of Medicine, he also co-founded the biotech company CohBar, served on numerous scientific advisory panels and Boards of Directors and was a Vice President at Bayer Corp and a Senior Vice President at Merck Pharmaceuticals. A prolific author, Dr. Amatruda has published over 150 papers, abstracts, reviews, and book chapters, primarily on diabetes and cardiovascular disease. He received a BA from Yale University, an MD from the Medical College of Wisconsin and completed clinical training in medicine and fellowship in endocrinology and metabolism at the Johns Hopkins Hospital.

Jennifer Cermak, PhD

Senior Vice President, Clinical Development

A seasoned leader in the research and development of drugs and medical devices, Dr. Jennifer Cermak has two decades of related experience. Having co-founded and managed multiple biotechnology startup companies, Dr. Cermak has successfully led every aspect of the production of life-changing pharmaceuticals from start to finish and brought them to market. She holds a PhD in pathology from Boston University School of Medicine, and she completed her postdoctoral fellowship in the Department of Surgery at Harvard Medical School.

Tristan Edwards

Co-Founder, President & Chief Investment Officer

Tristan Edwards is Co-founder, President, and Chief Investment Officer of Life Biosciences. He also sits on the Boards of Continuum Biosciences, Animal Biosciences, Senolytic Therapeutics and Jumpstart Fertility. Tristan brings extensive global financial capital markets, regulatory compliance and fiduciary oversight experience to the group, following a 16-year investment career spanning leading financial organizations across Australia, London, HK and Singapore. Having recognized the opportunity to leverage this experience in an entrepreneurial environment, he has subsequently moved to pursue his passion for helping create a scalable platform for financing and enabling the world’s best scientists and thought leaders to create change. Tristan’s professional background has been in senior investment roles at leading financial groups such as Goldman Sachs, Brevan Howard, Trafalgar Capital and Mosaic Asset Management. He started his career with the Australian Commonwealth Department of Finance. Tristan has a degree in commerce from the University of Tasmania and held the CFA, CMT and CPA designations.

Sree Kant, MBA, MPH

Head of Business Development

Sree Kant is focused on new scientific investments and strategic partnerships for Life Biosciences. Sree comes to Life with 18 years of varied healthcare and pharmaceutical industry experience. He previously was the head of early partnering strategy for Pfizer, working across different therapeutic areas/technologies and geographies with Academia, VCs/Banks, CROs, and other strategic partners. Sree was also a Principal at the Boston Consulting Group advising large pharma and biotech on R&D strategy as well as large M&A. He has an MBA from the Indian Institute of Management and an MPH from the Harvard School of Public Health. Sree is an invited speaker at key industry events and conferences on subjects of R&D strategy, innovative partnering models, industry-academia collaborations, early-stage technologies and investments, etc.

Brian Malone, FCA

Chief Financial Officer

Brian Malone brings over 35 years of experience in financial services, working with investment firms in Ireland, London and Boston. Brian was the Chief Financial Officer of Longwood Fund Management and also served as the first CFO/COO of many of the companies that Longwood incubated including some that went on to be NASDAQ listed. Most recently, he was the Senior Vice President of Finance at Axial Biotherapeutics, Inc., where he was responsible for all aspects of finance, operations, and information technology. Brian has an Honors Degree in science from University College Dublin and is a Fellow of the Irish Institute of Chartered Accountants. He recently completed a post-graduate course in strategy for pharma and biotech industries.

Kimberly McGonagle

Director, People & Culture

Kimberly McGonagle has more than 13 years of experience in human resources across a breadth of disciplines such as talent acquisition, talent management and development, total rewards, labor and employee relations, compliance and HR information systems. Kim served as Human Resources Director for True North Venture Partners, a venture capital firm that invests in clean and sustainable technologies; she focused on their two east coast portfolio companies, Harvest Power and Nanostone Water. In this role, she served as the HR leader for over 400 employees throughout the US, Canada, Europe and China. Prior to this, Kim spent 10 years at ABM Industries where she held various roles within the HR team of the Fortune 500 facilities services firm. Kim has a BS in business and economics from SUNY Oneonta and holds PHR and SHRM-CP certifications.

David Setboun, PharmD, MBA

Vice President

David Setboun brings 20 years of experience in general management and commercial for biopharma companies in Europe and Americas. Previously, he served as VP and General Manager for Biogen France. Prior to his work at Biogen, he held different senior executive positions at AstraZeneca, Eli Lilly, and Sanofi. He brought to market numerous treatments and technologies across a broad range of therapeutic areas. He holds a PharmD from Paris XI University and an HEC MBA & Advance Management Program from Harvard Business School.

Amit Shashank

General Counsel

Amit Shashank is a strategically-oriented global leader, with more than twenty years of international experience in technology and business services organizations. As General Counsel, he oversees Life Biosciences’s government affairs, legal, and compliance initiatives. Amit is a leader in navigating complex regulatory approvals and developing global strategic alliances that span mergers and acquisitions, commercial transactions, and all phases of corporation financings. On two separate occasions, Amit has led companies toward commercializing and liquidity events which include initial public offerings (IPO). Most recently, Amit served as Executive Vice President, General Counsel and Secretary of Aricent, a global R&D engineering and design powerhouse, which under his leadership as part of the executive team, grew to over 10,000 employees. In 2018, Amit was instrumental in supporting KKR & Co. in the sale of Aricent to Altran Technologies (EPA: ALT) for $2 billion. Prior to Aricent, Amit served as Executive Vice President, General Counsel, Chief Compliance Officer, and Secretary at ExlService Holdings, Inc. (NASDAQ: EXLS), an operations management and analytics company with more than 20,000 employees globally, where he led the IPO and NASDAQ listing of the company. Amit began his career at Shearman and Sterling LLP after graduating from The University of Michigan Law School, where he was editor-in-chief of the Michigan Journal of International Law. Amit is also a Rhodes Scholar and an adjunct professor at Columbia University Law School.

Michael Torres

Vice President, Global Corporate Affairs

Michael Torres is a senior corporate communications executive with more than 15 years of experience at several Fortune 500 companies. Most recently, Torres served as Vice President of Global Corporate Affairs for the Americas at InterContinental Hotels Group (IHG), where he was responsible for providing strategic counsel that protected and enhanced the reputation of IHG and its family of 15 hotel brands within the company’s largest operating region. As Senior Director of Global Corporate Communications at PepsiCo, Torres provided strategic internal and external corporate and executive communications as well as reputation risk/issues management counsel and direction for PepsiCo’s $1 billion Global Research and Development Division. Before joining PepsiCo, Torres held several leadership positions at Anheuser-Busch and AB InBev, the world’s largest brewer. He began his career in the public affairs practice at Fleishman-Hillard Inc., where he counseled senior management of Fortune 500 companies and supervised several critical communications projects. A native of Los Angeles, California, Torres holds a bachelor’s degree in sociology from the University of California Los Angeles and is an alumnus of Anheuser-Busch’s Leadership Development program, the AB InBev/Stanford University Graduate School of Business Advanced Marketing Executive Program and the AFL-CIO organizing Institute.

Nick Ventresca

Chief Technology Officer

Nick Ventresca brings over 20 years of experience in information technology for large multi-national organizations, mid-sized biopharmas and startup biotechs. Nick has broad international expertise implementing innovative scientific and patient-centric technology. Most recently, he grew strategic IT solutions for late-stage biotechs now commercializing. Previously, he served as CIO for high-profile organizations including Ariad (now Takeda), Genzyme (now Sanofi), Charles River Laboratories, Visiting Nurse Service of New York and Warner Lambert (now Pfizer), and was Chief Technology Officer for Pepsi Cola International. Nick is a graduate of Fordham University with a BS in biology and studied for two years at the La Sapienza School of Medicine in Rome, Italy.